Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
mBio ; 15(4): e0211423, 2024 Apr 10.
Article in English | MEDLINE | ID: mdl-38470050

ABSTRACT

Multidrug-resistant bacteria such as the opportunistic pathogen Pseudomonas aeruginosa, which causes life-threatening infections especially in immunocompromised individuals and cystic fibrosis patients, pose an increasing threat to public health. In the search for new treatment options, P. aeruginosa uridine diphosphate-glucose pyrophosphorylase (PaUGP) has been proposed as a novel drug target because it is required for the biosynthesis of important virulence factors and linked to pathogenicity in animal models. Here, we show that UGP-deficient P. aeruginosa exhibits severely reduced virulence against human lung tissue and cells, emphasizing the enzyme's suitability as a drug target. To establish a basis for the development of selective PaUGP inhibitors, we solved the product-bound crystal structure of tetrameric PaUGP and conducted a comprehensive structure-function analysis, identifying key residues at two different molecular interfaces that are essential for tetramer integrity and catalytic activity and demonstrating that tetramerization is pivotal for PaUGP function. Importantly, we show that part of the PaUGP oligomerization interface is uniquely conserved across bacterial UGPs but does not exist in the human enzyme, therefore representing an allosteric site that may be targeted to selectively inhibit bacterial UGPs.IMPORTANCEInfections with the opportunistic bacterial pathogen Pseudomonas aeruginosa are becoming increasingly difficult to treat due to multidrug resistance. Here, we show that the enzyme uridine diphosphate-glucose pyrophosphorylase (UGP) is involved in P. aeruginosa virulence toward human lung tissue and cells, making it a potential target for the development of new antibacterial drugs. Our exploration of P. aeruginosa (Pa)UGP structure-function relationships reveals that the activity of PaUGP depends on the formation of a tetrameric enzyme complex. We found that a molecular interface involved in tetramer formation is conserved in all bacterial UGPs but not in the human enzyme, and therefore hypothesize that it provides an ideal point of attack to selectively inhibit bacterial UGPs and exploit them as drug targets.


Subject(s)
Pseudomonas Infections , Virulence Factors , Animals , Humans , Virulence Factors/genetics , Pseudomonas aeruginosa , Anti-Bacterial Agents/pharmacology , Pseudomonas Infections/microbiology , Glucose , Uridine Diphosphate
2.
Nat Commun ; 11(1): 4723, 2020 09 18.
Article in English | MEDLINE | ID: mdl-32948778

ABSTRACT

O-Acetylation of the capsular polysaccharide (CPS) of Neisseria meningitidis serogroup A (NmA) is critical for the induction of functional immune responses, making this modification mandatory for CPS-based anti-NmA vaccines. Using comprehensive NMR studies, we demonstrate that O-acetylation stabilizes the labile anomeric phosphodiester-linkages of the NmA-CPS and occurs in position C3 and C4 of the N-acetylmannosamine units due to enzymatic transfer and non-enzymatic ester migration, respectively. To shed light on the enzymatic transfer mechanism, we solved the crystal structure of the capsule O-acetyltransferase CsaC in its apo and acceptor-bound form and of the CsaC-H228A mutant as trapped acetyl-enzyme adduct in complex with CoA. Together with the results of a comprehensive mutagenesis study, the reported structures explain the strict regioselectivity of CsaC and provide insight into the catalytic mechanism, which relies on an unexpected Gln-extension of a classical Ser-His-Asp triad, embedded in an α/ß-hydrolase fold.


Subject(s)
Bacterial Capsules/chemistry , Bacterial Capsules/metabolism , Neisseria meningitidis, Serogroup A/metabolism , Polysaccharides, Bacterial/chemistry , Polysaccharides, Bacterial/metabolism , Acetylation , Acetyltransferases , Antibodies, Bacterial , Bacterial Capsules/genetics , Bacterial Capsules/immunology , Bacterial Vaccines/immunology , Hexosamines , Models, Molecular , Neisseria meningitidis, Serogroup A/genetics , Polysaccharides, Bacterial/genetics , Polysaccharides, Bacterial/immunology , Protein Conformation
3.
J Biol Chem ; 295(17): 5771-5784, 2020 04 24.
Article in English | MEDLINE | ID: mdl-32152227

ABSTRACT

Actinobacillus pleuropneumoniae (App) is the etiological agent of acute porcine pneumonia and responsible for severe economic losses worldwide. The capsule polymer of App serotype 1 (App1) consists of [4)-GlcNAc-ß(1,6)-Gal-α-1-(PO4-] repeating units that are O-acetylated at O-6 of the GlcNAc. It is a major virulence factor and was used in previous studies in the successful generation of an experimental glycoconjugate vaccine. However, the application of glycoconjugate vaccines in the animal health sector is limited, presumably because of the high costs associated with harvesting the polymer from pathogen culture. Consequently, here we exploited the capsule polymerase Cps1B of App1 as an in vitro synthesis tool and an alternative for capsule polymer provision. Cps1B consists of two catalytic domains, as well as a domain rich in tetratricopeptide repeats (TPRs). We compared the elongation mechanism of Cps1B with that of a ΔTPR truncation (Cps1B-ΔTPR). Interestingly, the product profiles displayed by Cps1B suggested processive elongation of the nascent polymer, whereas Cps1B-ΔTPR appeared to work in a more distributive manner. The dispersity of the synthesized products could be reduced by generating single-action transferases and immobilizing them on individual columns, separating the two catalytic activities. Furthermore, we identified the O-acetyltransferase Cps1D of App1 and used it to modify the polymers produced by Cps1B. Two-dimensional NMR analyses of the products revealed O-acetylation levels identical to those of polymer harvested from App1 culture supernatants. In conclusion, we have established a protocol for the pathogen-free in vitro synthesis of tailored, nature-identical App1 capsule polymers.


Subject(s)
Actinobacillus Infections/microbiology , Actinobacillus pleuropneumoniae/chemistry , Actinobacillus pleuropneumoniae/enzymology , Bacterial Capsules/chemistry , Oligosaccharides/chemistry , Actinobacillus pleuropneumoniae/metabolism , Bacterial Capsules/enzymology , Bacterial Capsules/metabolism , Bacterial Proteins/chemistry , Bacterial Proteins/metabolism , Chemistry Techniques, Synthetic , Enzymes, Immobilized/chemistry , Enzymes, Immobilized/metabolism , Humans , Oligosaccharides/chemical synthesis , Oligosaccharides/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...